17 episodios

Video interviews and press conference footage from the AACR 2012 Annual Meeting in Chicago, March 31st to April 4th, 2012.

AACR 2012 Annual Meeting, Chicago ecancer

    • Medicina

Video interviews and press conference footage from the AACR 2012 Annual Meeting in Chicago, March 31st to April 4th, 2012.

    • video
    Nutrition and supplements for cancer survivors: Prof Susan Mayne - Yale University, Connecticut, USA

    Nutrition and supplements for cancer survivors: Prof Susan Mayne - Yale University, Connecticut, USA

    Prof Susan Mayne talks about her presentation at the AACR 2012 Annual meeting on the scientific evidence on supplements and nutrition for the growing population of cancer survivors.

    • 10 min
    • video
    Effects of metformin in pancreatic cancer with diabetes: Prof Donghui Li - University of Texas MD Anderson Cancer Center

    Effects of metformin in pancreatic cancer with diabetes: Prof Donghui Li - University of Texas MD Anderson Cancer Center

    Prof Li talks about the new findings with the drug metformin in diabetic patients with pancreatic cancer. Preliminary data has shown that 117 patients who use metformin showed a 4-month increase in overall survival and 18 percent increase in first year survival.

    • 3 min
    • video
    Targeting the cancer genome: Dr Bill Sellers - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

    Targeting the cancer genome: Dr Bill Sellers - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

    Dr Bill Sellers talks about his session at the AACR 2012 Annual Meeting on the five key issues on the genetic basis of cancer drug development.

    Dr Sellers mentions previously successful drugs, such as gleevec, and how there needs to be a greater understanding of the cancer genome, which will lead to more therapies for diseases once thought to be unaffected by this type of treatment.

    • 9 min
    • video
    Metformin to slow prostate cancer growth: Dr Anthony Joshua - Princess Margaret Hospital, Toronto, Canada

    Metformin to slow prostate cancer growth: Dr Anthony Joshua - Princess Margaret Hospital, Toronto, Canada

    The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

    Dr Joshua, from the Princess Margaret Hospital, University Health Network in Toronto, presented the data at the AACR Annual Meeting 2012

    • 5 min
    • video
    Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center

    Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center

    Dr Naing presents data at a press conference on a combination of targeted therapies that may be effective against relapsed or recurrent Ewing’s sarcoma or desmoplastic small-round-cell tumours. The results come from a phase I trial presented at the AACR Annual Meeting 2012.

    • 4 min
    • video
    Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

    Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

    Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading the androgen receptor protein.

    Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012.

    • 5 min

Top podcasts de Medicina

Más de ecancer